SHR 1603
Alternative Names: SHR-1603Latest Information Update: 28 Dec 2021
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (IV, Infusion)
- 22 Mar 2021 Jiangsu HengRui Medicine terminates phase I trial in Lymphoma (Second-line therapy or greater) and Solid tumours (Late stage disease) in China due to business decision (IV) (NCT03722186)